Design and synthesis of isoquinolines and benzimidazoles as RAF kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 8, 2011, Pages 2264-2269

  Buchstaller, Hans Peter ^a   Burgdorf, Lars ^a   Finsinger, Dirk ^a   Stieber, Frank ^a   Sirrenberg, Christian ^a   Amendt, Christiane ^a   Grell, Matthias ^a   Zenke, Frank ^a   Krier, Mireille ^a  

^a Merck Serono GmbH   (Germany)

Author keywords

Benzimidazole; Isoquinoline; RAF kinase

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; HETEROCYCLIC AMINE; ISOQUINOLINE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; SORAFENIB;

ARTICLE; DRUG DESIGN; DRUG SYNTHESIS; ENZYME INHIBITION; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

BENZIMIDAZOLES; BINDING SITES; CATALYTIC DOMAIN; COMPUTER SIMULATION; DRUG DESIGN; ISOQUINOLINES; PROTEIN KINASE INHIBITORS; RAF KINASES; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79953281702     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.02.108     Document Type: Article

References (44)

1. N. Dumaz, and R. Marais Eur. J. Biol. Chem. 278 2003 29819
2. C. Wellbrock, M. Karasarides, and R. Marais Nat. Rev. Mol. Cell Biol. 5 2004 875
3. A. Chiloeches, and R. Marais Targets for Cancer Chemotherapy Transcription Factors and Other Nuclear Proteins 2002 Humana Press Inc. Totowa, NJ 179 206
4. W. Kolch Biochem. J. 351 2000 289
5. C.K. Weber, J.R. Slupsky, C. Herrmann, M. Schuler, U.R. Rapp, and C. Block Oncogene 19 2000 169
6. C.A. Pritchard, M.L. Samuels, E. Bosch, and M. McMahon Mol. Cell. Biol. 15 1995 6430
7. T. Minamoto, M. Mai, and Z. Ronai Cancer Detect. Prev. 24 2000 1
8. S.T. Yuen, H. Davies, T.L. Chan, J.W. Ho, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, W.W. Tsui, A.S. Chan, P.A. Futreal, M.R. Stratton, R. Wooster, and S.Y. Leung Cancer Res. 62 2002 6451
9. S.J. Heidorn, C. Milagre, S. Whittaker, A. Nourry, I. Niculescu-Duvas, N. Dhomen, J. Hussain, J.S. Reis-Filho, C.J. Springer, C. Pritchard, and R. Marais Cell 140 2010 209
10. C.K. Weber, J.R. Slupsky, H.A. Kalmes, and U.R. Rapp Cancer Res. 61 2001 3595
11. M.J. Garnett, S. Rana, H. Paterson, D. Barford, and R. Marais Mol. Cell 20 2005 963
12. L.K. Rushworth, A.D. Hindley, E. O'Neill, and W. Kolch Mol. Cell. Biol. 26 2006 2262
13. S. Schubbert, K. Shannon, and G. Bollag Nat. Rev. Cancer 7 2007 295
14. M.J. Garnett, and R. Marais Cancer Cell 6 2004 313
15. V. Khazak, I. Astsaturov, I.G. Serebriiskii, and E.A. Golemis Expert Opin. Ther. Targets 11 2007 1587
16. H.-F. Li, Y. Chen, S.-S. Rao, X.-M. Chen, H.-C. Liu, J.-H. Qin, W.-F. Tang, Y. Wang, X. Zhou, and T. Lu Curr. Med. Chem. 17 2010 1618
17. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, R. Alvarado, M.J.C. Ludlam, D. Stokoe, S.L. Gloor, G. Vigers, T. Morales, I. Aliagas, B. Liu, S. Sideris, K.P. Hoeflich, B.S. Jaiswal, S. Seshagiri, H. Koeppen, M. Belvin, L.S. Friedman, and S. Malek Nature 464 2010 431
18. P.I. Poulikakos, C. Zhang, G. Bollag, K.M. Shokat, and N. Rosen Nature 464 2010 427
19. T.B. Lowinger, B. Riedl, J. Dumas, and R.A. Smith Curr. Pharm. Des. 8 2002 2269
20. S. Ramurthy, S. Subramanian, M. Aikawa, P. Amiri, A. Costales, J. Dove, S. Fong, J.M. Jansen, B. Levine, S. Ma, C.M. McBride, J. Michaelian, T. Pick, D.J. Poon, S. Girish, C.M. Shafer, D. Stuart, L. Sung, and P.A. Renhowe J. Med. Chem. 51 2008 7049
21. P.T.C. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, V.M. Good, C.G. Project, C.M. Jones, C.J. Marshall, C.J. Springer, D. Barford, and R. Marais Cell 116 2004 855
22. The structural information about the B-RAF kinase domain (SWID: P15056) is used as surrogate for the kinase domain of c-RAF (RAF1) (SWID: P04049). The residue identity is 81.7%. The hinge region has the identical sequence.
23. A. Gopalsamy, G. Ciszewski, M. Shi, D. Berger, Y. Hu, F. Lee, L. Feldberg, E. Frommer, S. Kim, K. Collins, D. Wojciechowicz, and R. Mallon Bioorg. Med. Chem. Lett. 19 2009 6890
24. J. Tang, T. Hamajima, M. Nakano, H. Sato, S.H. Dickerson, and K.E. Lackey Bioorg. Med. Chem. Lett. 18 2008 4610
25. D. Niculescu-Duvaz, C. Gaulon, H.P. Dijkstra, I. Niculescu-Duvaz, A. Zambon, D. Ménard, B.M.J.M. Suijkerbuijk, A. Nourry, L. Davies, H.A. Manne, F. Friedlos, L.M. Ogilvie, D. Hedley, S. Whittaker, R. Kirk, A. Gill, R.D. Taylor, F.I. Raynaud, J. Moreno-Farre, R. Marais, and C.J. Springer J. Med. Chem. 52 2009 2255
26. A. Zambon, D. Ménard, B.M.J.M. Suijkerbuijk, I. Niculescu-Duvaz, S. Whittaker, D. Niculescu-Duvaz, A. Nourry, L. Davies, H.A. Manne, F. Lopes, N. Preece, D. Hedley, L.M. Ogilvie, R. Kirk, R. Marais, and C.J. Springer J. Med. Chem. 53 2010 5639
27. CCDC GOLD version 4.1 with default screening parameters and without any constraints. The binding mode was validated by the successful reproduction of the crystal structure via redocking, which is considered as validation for the docking of similar structures.
28. K. Verschueren, G. Toth, D. Tourwé, M. Lebl, G. Van Binst, and V. Hruby Synthesis 1992 458
29. Z. Guo, E.D. Dowdy, W.-S. Li, R. Polniaszek, and E. Delaney Tetrahedron Lett. 42 2001 1843
30. V. VanRheenen, R.C. Kelly, and D.Y. Cha Tetrahedron Lett. 17 1976 1973
31. D.S. Kashdan, J.A. Schwartz, and H. Rapoport J. Org. Chem. 47 1982 2638
32. Buchstaller, H.-P.; Burgdorf, L.; Finsinger, D.; Amendt, C.; Grell, M.; Sirrenberg, C.; Zenke, F. PCT Int. Appl., WO2005/082858
33. Chem. Abstr. 2005, 143, 286297.
34. In a final reaction volume of 25 μL, human c-RAF (5-10 mU, Millipore) was incubated with 25 mM Tris pH 7.5, 0.02 mM EGTA, 0.66 mg/mL myelin basic protein, 10 mM Mg acetate and [γ-33P-ATP] (specific activity approx. 500 cpm/pmol). The reaction was initiated by the addition of the MgATP mix. After incubation for 40 min at room temperature, the reaction was stopped by the addition of 3% phosphoric acid solution. The reaction was then spotted onto a P30 filtermat and washed prior to drying and scintillation counting. All measurements were performed in duplicates.
35. Unpublished results.
36. M. Hasegawa, N. Nishigaki, Y. Washio, K. Kano, P.A. Harris, H. Sato, I. Mori, R.I. West, M. Shibahara, H. Toyoda, L. Wang, R.T. Nolte, J.M. Veal, and M. Cheung J. Med. Chem. 50 2007 4453
37. S. Kostic, V. Soskic, and J. Joksimovic Arzneim. Forsch. 44 1994 697
38. R. Zou, J.C. Drach, and L.B. Townsend J. Med. Chem. 40 1997 802
39. H. Graubaum, D. Martin, C. Csunderlik, H.-H. Glatt, R. Bacaloglu, and M. Malurea-Munteanu Z. Chem. 24 1984 57
40. P. Louvet, G. Lallement, I. Pernot-Marino, C. Luu-Duc, and G. Blanchet Eur. J. Med. Chem. 28 1993 71
41. L. Garuti, M. Roberti, and G. Gentilomi Farmaco 55 2000 35
42. Buchstaller, H.-P.; Burgdorf, L.; Stieber, F.; Amendt, C.; Grell, M.; Sirrenberg, C.; Zenke, F. PCT Int. Appl., WO2005/082862
43. Chem. Abstr. 2005, 143, 266924.
44. Kinetic solubility of the compounds was determined according to B. Hoelke, S. Gieringer, M. Arlt, and C. Saal Anal. Chem. 81 2009 3165 (HPLC method) using phosphate buffer (50 mM). 10f: 4.2 μg/ml; 10m: <1 μg/ml; 10n: 16.4 μg/ml; 19c: 12.4 μg/ml; 19n: 82.7 μg/ml; 19q: 81.2 μg/ml